Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 19, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal 2011 on Tuesday, May 3, 2011...
-
Apr 13, 2011
Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to...
-
Apr 12, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of...
-
Mar 14, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Barclays Capital 2011 Global...
-
Mar 1, 2011
Perrigo (Nasdaq: PRGO;TASE) today announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the...
-
Feb 28, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi 2011 Global Health Care...
-
Feb 22, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for calcipotriene 0.005% and betamethasone...
-
Feb 21, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that it has begun selling OTC infant formula to Costco in Canada. The product will be sold under Costco's...
-
Feb 17, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that it has entered into an exclusive agreement with AgaMatrix, Inc. to sell and distribute blood glucose...
-
Feb 10, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by...
-
Feb 1, 2011
-- Fiscal second quarter revenue from continuing operations increased $135 million, or 23%, to $718 million -- Fiscal second quarter GAAP income from...
-
Jan 26, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on March...
-
Jan 20, 2011- Paddock Labs is a privately-held manufacturer and marketer of generic Rx pharmaceutical products
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock...
-
Jan 17, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its second quarter fiscal 2011 on Tuesday, February 1,...
-
Jan 7, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 29th Annual J.P. Morgan...
-
Dec 13, 2010
IR Global Rankings ("IRGR"), the most comprehensive technical ranking system for investor relations websites, corporate governance practices and...
-
Dec 10, 2010
JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 12/10/10 -- www.stockcall.com/ offers investors comprehensive research on the drug related products industry and has completed analytical research on...
-
Nov 29, 2010
In the news release, Perrigo Announces Launch of Naproxen Sodium Soft Gels - Generic Equivalent to Aleve® Liquid Gels, issued 29-Nov-2010 by Perrigo over PR Newswire, we are advised by the...
-
Nov 29, 2010
Perrigo (Nasdaq: PRGO;TASE) today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug...
-
Nov 29, 2010
Perrigo (Nasdaq: PRGO; TASE) today announced that it has launched Naproxen Sodium Soft Gels. The product is the generic equivalent of Bayer...
-
Nov 23, 2010
IR Global Rankings (IRGR) is pleased to announce that it will collaborate with Institutional Investor magazine on a series of Investor Relations events...
-
Nov 10, 2010
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse Annual...
-
Nov 9, 2010
JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 11/09/10 -- www.wallstreetequityresearch.com brings investors market knowledge on the aspects moving the drug related products stocks, and offers...
-
Nov 2, 2010
Fiscal first quarter revenue from continuing operations increased $113 million, or 21 percent, to a record $641 million Fiscal first quarter...
-
Oct 27, 2010
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...
-
Oct 19, 2010
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2011 on Tuesday, November...
-
Sep 24, 2010
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...
-
Sep 8, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically...
-
Sep 2, 2010
JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 09/02/10 -- www.wallstreetequityresearch.com gives shareholders valuable insight on drug related products stocks Perrigo Co. (NASDAQ: PRGO) and NBTY...
-
Aug 25, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA clearance on August 23, 2010 to manufacture infant formula liquid concentrate and ready-to-use products through its partner...
-
Aug 19, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clobetasol propionate shampoo,...
-
Aug 12, 2010
-- Full-year revenue from continuing operations increased $262 million, or 13 percent, to a record $2.27 billion. -- Adjusted income from continuing operations for the full year increased 50...
-
Aug 11, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on September 14, 2010 to shareholders of record...
-
Jul 30, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for butoconazole nitrate vaginal...
-
Jul 29, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2010 on Thursday, August 12, 2010 at approximately 8:00 a.m. (ET). The Company...
-
Jul 26, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC)...
-
Jul 14, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Emulsion...
-
Jun 29, 2010
Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of Fexofenadine HCl 180 mg and 60 mg tabs, plus...
-
Jun 25, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging & Leisure Conference...
-
Jun 15, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Executive Vice President and CFO Judy Brown will present at the 31st Annual Goldman Sachs Global Healthcare Conference on...
-
Jun 3, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for...
-
Jun 2, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit...
-
May 26, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium...
-
May 24, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi Investment Research Global Health Care Conference on Wednesday, May...
-
May 5, 2010
Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute Dextromehtorphan Polistirex Extended Release Suspension Cough...
-
May 3, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has closed the previously announced acquisition of PBM Holdings, Inc., the world's largest manufacturer of infant formula for...
-
Apr 29, 2010
-- Fiscal third quarter revenue from continuing operations increased $32 million, or 6%, to $538 million -- Fiscal third quarter adjusted income from continuing operations increased 49% to $70...
-
Apr 28, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on June 15, 2010 to shareholders of record on May...
-
Apr 16, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2010 on Thursday, April 29, 2010 at approximately 8:00 a.m. (ET). The...
-
Apr 15, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has been named as an authorized generic partner by Ferndale Laboratories and has launched an authorized generic of Analpram HC®...